source · text/markdown
source_0e6bfef5d571493a
sha256 3c1516dc4998fffc3c72b1e290e9b0edd8cd049b84340a6ceec50946ef5b8646
by researka:v2 · 2026-05-28 22:28:18.077071+04:00
This synthesis tests the thesis that evidence for Coenzyme Q10 ubiquinol is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Coenzyme Q10, particularly its reduced form ubiquinol, has been investigated as a potential intervention for age-related decline owing to its dual role in mitochondrial bioenergetics and antioxidant defense. This structured evidence synthesis evaluated 63 curated reference papers encompassing randomized trials, observational cohorts, and systematic reviews to characterize the context-dependent profile of CoQ10/ubiquinol across cardiometabolic, immune, and longevity outcomes. Anti-inflammatory effects appear meaningful but heterogeneous: an umbrella meta-analysis demonstrated CoQ10 significantly reduced serum C-reactive protein (P = 0.042) and oxidative stress markers (Varnousfaderani 2023), and a pooled analysis of coronary artery disease trials confirmed decreases in inflammatory biomarkers (P < 0.001) (Jorat 2019). The anti-aging case for CoQ10/ubiquinol as currently constituted is incomplete: mechanistic plausibility in mitochondrial function and inflammation coexists with mixed or sparse human-RCT evidence on hard functional endpoints such as gait speed or sarcopenia progression, and optimal dose-response relationships in aging populations remain unestablishe
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "52b0a5cc-3d62-4c18-b98c-bc8be345d00b",
"title": "Research Synthesis: Coenzyme Q10 Ubiquinol \u2014 full paper"
}